Growth through Bioinks CELLINK’s continued bioprinting innovations and recent BIO ONE and Vivoink launches indicate a strong opportunity to upsell advanced bioinks and printing solutions to existing customers and new life science labs seeking translational research capabilities.

Strategic Partnerships Recent collaborations with Ossiform to commercialize printable bioinks suggest a channel strategy that can be emulated; explore co-marketing and bundled solutions with Ossiform and similar biomaterial partners to extend reach into tissue engineering and regenerative medicine labs.

Clinical Translation Focus Vivoink targets regulatory-grade bioink for clinical translational journeys, signaling a customer segment of academic and clinical researchers; propose compliant, end-to-end printing workflows and service packages that reduce time to in vivo studies.

Expansion Via Automation As part of the BICO ecosystem with a broad installed base and lab automation offerings, there is a cross-sell potential to offer automated bioprinting workflows, integrated with existing lab automation software and equipment to improve throughput for pharma and biotech customers.

SMB and Expansion Readiness CELLINK’s size and revenue profile align with mid-market life science buyers; tailor affordable, scalable solutions (starter kits, entry-level printers, and flexible bioink bundles) aimed at mid-sized biotech startups and university labs looking to democratize access to bioprinting.